NEURACAP
Sector OutlookPublished · 22 pages · Free to read

Diagnostic and Testing Equipment Sector Outlook — September 2026

A sector outlook on Diagnostic and Testing Equipment, covering 26 public companies and their precedent transactions, for owners, boards and acquirers assessing where value sits between consumables-led and placement-led business models. Valuation basis: EV / EBITDA (CY2027E), as of September 28, 2026.

For information only. Not an appraisal or a fairness opinion.

What moved since: Diagnostic and Testing Equipment M&A update, 14–28 September 2026

Key figures

Sector median multiple
21.1x
EV / EBITDA (CY2027E), 11 of 26 rated
Top of the range
48.5x
Highest multiple among rated names
Bottom of the range
9.0x
Lowest multiple among rated names
Consumables-led group median
34.8x
vs 15.3x for procedure-led devices

Read the report

NeuraCap

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › DIAGNOSTIC AND TESTING EQUIPMENT

Diagnostic and Testing Equipment: Two Prices, One Label

How this market marks consumables annuities against instrument placements, and what sits behind the gap between the two ends.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E)

Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice

1

1 / 22

Executive summary

Diagnostic and testing equipment trades under one sector label but prices as two distinct businesses. Among the 11 rated companies, the median forward multiple is 21.1x, with a range from 9.0x to 48.5x; reagent and consumables-led names sit at 34.8x against 15.3x for procedure-led device makers. Precedent transactions echo the same split, valuing consumables-led targets on earnings and menu-stage targets on revenue. For owners and acquirers, the share of contracted pull-through revenue behind a placed instrument base is what the market appears to reward most.

Key findings

  • Sector median multiple sits at 21.1x forward EV/EBITDA across 11 rated names.
  • Consumables-led names trade at 34.8x versus 15.3x for procedure-led devices.
  • The rated range spans 9.0x to 48.5x, with three names at each extreme.
  • Higher-margin names trade at 18.2x versus 24.0x for lower-margin peers.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › DIAGNOSTIC AND TESTING EQUIPMENT

    Cover slide framing the Diagnostic and Testing Equipment sector outlook as of September 2026.

    This report looks at how the market prices diagnostic and testing equipment businesses as of September 2026, using forward EV/EBITDA on CY2027E consensus as the primary lens. What follows shows where the range sits, and what separates the top of it from the bottom.

    Everything on this page

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › DIAGNOSTIC AND TESTING EQUIPMENT Diagnostic and Testing Equipment: Two Prices, One Label How this market marks consumables annuities against instrument placements, and what sits behind the gap between the two ends. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E) Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    Contents page listing the five sections plus appendix that make up the report.

    We've structured this report so the bottom line comes first: section one carries the full finding, and everything after it builds the evidence behind that finding. A reader who only has time for one section still leaves with the complete picture.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line The Structure Behind the Price: Annuity Revenue at One End, Capital Cycles at the Other 02 The Landscape Five Groups Sit Under the Sector Label, and the Marks Differ Across Them 03 Valuation & Situations The Two Ends of This Market Are Far Apart, with Three Names at Each One 04 Precedent Transactions Earnings Frames for the Consumables Deals, Revenue Frames for the Menu-Stage Ones 05 Strategic Implications The Mix Between Boxes and Blades Is the Part an Owner Can Move 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Diagnostic and Testing Equipment Prices Consumables Annuities Apart from Placement-Led Devices

    Summary slide stating that consumables and reagent revenue commands a materially higher valuation than placement-led device revenue.

    Across the 11 companies with a forward estimate, the market prices this sector at a median of 21.1x forward EV/EBITDA, but the range runs from 9.0x to 48.5x. That spread tracks with how much of a company's revenue is contracted consumables and service rather than one-time instrument sales. So the sector label hides two different businesses, and knowing which one a company resembles matters more than its size.

    Everything on this page

    01 · THE BOTTOM LINE Diagnostic and Testing Equipment Prices Consumables Annuities Apart from Placement-Led Devices The full story on one page · figures on EV / EBITDA (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (11 of 26 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 Among the Names with a Forward Estimate, Buyers Mark Value off Forward Earnings The middle of the range sits at 21.1x forward CY2027E earnings, with 11 of the 26 companies carrying a forward estimate. A forward multiple already credits forecast growth, so a premium that survives it reads as durability rather than one good year. 2 The Two Ends of This Market Are Far Apart The top of the range is marked at 48.5x and the bottom at 9.0x, three names at each end of the 11 companies with a forward estimate. Our read is that where a company sits in that band is associated with how much of its revenue is contracted consumables and service, more than with its size. 3 Growth Ranks Only Loosely with Where Names Sit Across This Set's Range Among the 11 companies with a forward estimate, the six growing at 9% or better sit at 20.3x while the five below that mark sit at 24.0x. On a lens that already credits forecast growth, that ordering points to buyers weighing the durability of pull-through alongside the top-line rate. 4 The Consumables Side of the Sector Carries the Higher Mark Laboratory instruments and testing consumables sits at 34.8x on the 2 of its 5 names with a forward estimate, against 15.3x for procedure-based diagnostic and therapy devices on 6 of its 12 names. The small base at the top means those two names shape that figure, so treat it as a signal about pull-through economics rather than a sector-wide rate. 21.1x Sector median EV/EBITDA CY2027E consensus · 11 rated of 26 companies 48.5x Premium end EV/EBITDA vs 9.0x at the discount end top quartile (n=3) against bottom quartile (n=3) on EV/EBITDA — the spread the report explains 27 Transactions with disclosed terms 60 recorded in this tier · 1 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    Section divider introducing the market map of five business-model groups within the sector.

    Five groups sit under this sector label, and their forward multiples differ meaningfully. We'll walk through where the value sits before looking at individual companies.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE Five Groups Sit Under the Sector Label, and the Marks Differ Across Them Consumables-led groups sit above procedure-led groups on the forward earnings lens. 02 of 06 Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    Where the Value Sits: Consumables Menus at One End, Procedure Devices at the Other

    Map of the 26 approved companies grouped by business segment, showing median EV/EBITDA per group.

    We've grouped the 26 companies in this universe by business segment and plotted the median forward multiple for each. Consumables-menu businesses sit at one end of this map and procedure-device businesses sit at the other. That gap is the throughline for the rest of this report, so it's worth anchoring on before we go company by company.

    Everything on this page

    02 · MARKET MAP Where the Value Sits: Consumables Menus at One End, Procedure Devices at the Other 26 approved companies grouped by business segment · median EV / EBITDA (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 PROCEDURE-BASED DIAGNOSTIC AND THERAPY DEVICES 12 cos median 15.3x ABT DXCM PHG BIO NEOG INSP IRMD CBLL SSII SENS CV LUCD The biggest block by count, and the one closest to hospital procedure and capital budgets. LABORATORY INSTRUMENTS AND TESTING CONSUMABLES 5 cos median 34.8x RGEN NNNN KRMD OSUR DXR Where reagent rental and pull-through behind a placed instrument show up most directly. CLINICAL DIAGNOSTICS AND RESEARCH INSTRUMENTATION 4 cos median 21.2x WAT IDXX ILMN XGN Installed-base businesses whose instrument demand tracks pharma and academic capital cycles. RESEARCH-USE DETECTION PLATFORMS AND REAGENTS 3 cos 50.4x · 1 rated MRVI NAUT MXCT Funded from research budgets rather than reimbursement, so the economics read earlier-stage. ADJACENT MODELS 2 cos no rated names MLAB CARL Quality-testing and informatics businesses that sit beside the core diagnostics groups.

  6. 06
    02 · LANDSCAPE

    The Higher Marks Sit with Consumables Menus; Procedure Devices Sit with the Capital Cycle

    Detail on which segments carry the higher and lower multiples and why.

    The higher marks sit with groups selling consumables menus, and the lower marks sit with groups tied to the capital-equipment cycle. Our reading is that recurring, contracted revenue is what the market rewards here, not the segment label itself. Full company-level detail behind these medians sits in the appendix for anyone who wants to check a specific name.

    Everything on this page

    02 · LANDSCAPE The Higher Marks Sit with Consumables Menus; Procedure Devices Sit with the Capital Cycle Segment view of the approved universe · EV / EBITDA (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/EBITDA Names to know What they do — and why it matters Procedure-based diagnostic and therapy devices 12 46% 15.3x Abbott Laboratories (ABT) · DexCom, Inc. (DXCM) · +10 more The largest group by count. Twelve companies sit here, 46% of the set, and the six with a forward estimate sit at 15.3x. Revenue leans on procedure volumes and hospital capital budgets, the exposure marked most cautiously across this set. Laboratory instruments and testing consumables 5 19% 34.8x Repligen Corporation (RGEN) · Anbio Biotechnology Class A Ordinary Shares (NNNN) · +3 more Razor-and-blade economics, richer marks. Five companies, 19% of the set, and the 2 of them with a forward estimate sit at 34.8x. This is where consumables pull-through behind a placed instrument shows up most directly; with only two marks, those two names shape the figure. Clinical diagnostics and research instrumentation 4 15% 21.2x Waters Corporation (WAT) · IDEXX Laboratories, Inc. (IDXX) · +2 more Menu breadth meets capital cycles. Four companies, 15% of the set, with the 2 carrying a forward estimate at 21.2x. Instrument demand here moves with pharma and academic capital budgets, while service contracts and reagent attach provide the steadier layer. Research-use detection platforms and reagents 3 12% 50.4x n=1 Maravai LifeSciences Holdings, Inc. (MRVI) · Nautilus Biotechnology, Inc. (NAUT) · +1 more One estimate, earlier-stage economics. Three companies, 12% of the set, and a single name carries a forward estimate, at 50.4x. Demand is funded from research budgets rather than reimbursement, so read that figure as one name's mark rather than a group rate. Adjacent models 2 8% — Mesa Laboratories, Inc. (MLAB) · Carlsmed, Inc. (CARL) Two names, no forward estimate. Two companies, 8% of the set — Mesa Laboratories, Inc. (MLAB) and Carlsmed, Inc. (CARL) — and neither carries a forward earnings estimate. They sit beside the core groups on quality-testing and informatics models, so the earnings lens does not reach them here.

  7. 07
    SECTION 03

    03

    Section divider introducing the ranked valuation view across the 11 rated companies.

    The two ends of this market are far apart, with three names sitting at each extreme. Next we rank the full rated set from top to bottom.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS The Two Ends of This Market Are Far Apart, with Three Names at Each One A ranked read of the 11 companies with a forward estimate, top of the range against bottom of the range. 03 of 06 Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    Reagents and Consumables Sit at the Top of the Range; Capital-Equipment Exposure Sits at the Bottom

    Ranked chart of all 11 rated companies on EV/EBITDA (CY2027E), from 48.5x at the top to 9.0x at the bottom.

    Sorting the 11 rated companies by forward multiple, the top of the range sits at 48.5x and the bottom at 9.0x, against a sector median of 21.1x. Reagent and consumables exposure clusters at the top of this ranking, and capital-equipment exposure clusters at the bottom. So the ranking itself is a map of revenue quality as the market sees it today.

    Everything on this page

    03 · PUBLIC MARKET VALUATION Reagents and Consumables Sit at the Top of the Range; Capital-Equipment Exposure Sits at the Bottom EV / EBITDA (CY2027E) · all 11 rated companies, sorted descending · sector median 21.1x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (11 of 26 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / EBITDA (CY2027E) basis. Panel commentary is a NeuraCap view. Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 48.5x CORE · median 21.1x DISCOUNT · median 9.0x Sector median 21.1x WHAT SEPARATES THE TWO ENDS The top end prices reagents. The three names at the top of the range sit at 48.5x on forward CY2027E earnings: Maravai LifeSciences Holdings, Inc. (MRVI), Repligen Corporation (RGEN) and Bio-Rad Laboratories, Inc. (BIO). Two of the three sell reagents and consumables into someone else's workflow rather than capital equipment. The bottom end carries capital cycles. The three names at the bottom sit at 9.0x: Abbott Laboratories (ABT), Inspire Medical Systems, Inc. (INSP) and Koninklijke Philips N.V. (PHG). All three carry procedure or hospital capital-budget exposure, and in our read placement-led revenue is being marked more cautiously than pull-through revenue. Forward earnings already credit growth. The lens is CY2027E EV / EBITDA, so forecast growth is inside the number before the ranking starts; a premium that survives it reads as durability rather than a single strong year. Only 11 of the 26 companies carry a forward estimate, so each end of the range rests on three names.

  9. 09
    03 · VALUATION DRIVERS

    Profitability Separates the Two Ends: Names Above the 21% Margin Line Carry 18.2x Against 24.0x Below It

    Comparison of median multiples split by revenue-growth cohort and by EBITDA-margin cohort among the rated companies.

    Splitting the rated set at its own median growth rate, faster-growing names carry 20.3x; splitting at the median margin, higher-margin names carry 18.2x against 24.0x for lower-margin names. That second split runs the opposite way from what a simple growth story would predict. Our read is that buyers are weighing durability of pull-through alongside the growth rate itself, which is an association in this data rather than a proven cause.

    Everything on this page

    03 · VALUATION DRIVERS Profitability Separates the Two Ends: Names Above the 21% Margin Line Carry 18.2x Against 24.0x Below It Median EV / EBITDA (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=6; slower n=5; higher-margin n=6; lower-margin n=5). Driver readings are NeuraCap views on the supplied data — association, not causation. Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/EBITDA, median per cohort · growth split at 9% · EBITDA-margin split at 21% The Faster Half Sits Below the Slower Half on Forward Earnings Among the 11 companies with a forward estimate, the six growing at 9% or better sit at 20.3x and the five below that mark sit at 24.0x. The comparison rests on six names against five, so read it as a signal that the speed of the top line is not what separates the ends of this market. Reported Margin Is Not Tracking the Mark Either The more expensive half of the 11 companies with a forward estimate is priced at 27.2x against 13.6x for the cheaper half, and it carries the thinner reported margin. Margin here reflects where a company sits between instrument placements and consumables pull-through, so a thinner margin can sit with a menu still being built out. Coverage, Clearance and Menu Tenor Sit Behind the Durability Question What the forward lens is being asked to judge is whether the reagent and service stream behind a placed instrument holds. Contract tenor, reagent exclusivity and renewal history are the operating facts that sit under that judgment, and they differ name by name across this set. Non-Clinical Adjacencies Change the Shape of the Revenue Base Veterinary, food safety and bioprocess exposure inside this set is associated with a revenue base less tied to hospital and academic capital cycles. For an owner, that is a mix decision about which end markets the placed base serves, not a market-wide condition.

  10. 10
    03 · SITUATION MAP

    Three Names Pair a Premium Valuation with Faster Growth; Two Sit Below the Middle on Valuation and Growth

    Grid placing each rated company by valuation versus growth relative to the sector median and covered median growth.

    Cutting the rated set on the 21.1x sector median and the 9% covered median growth rate, three names pair a premium valuation with faster growth, while two sit below the middle on both measures. This is a map of where each company sits today, not a recommendation to act on any one of them. It's a useful starting point for a conversation about which situation a given business is actually in.

    Everything on this page

    03 · SITUATION MAP Three Names Pair a Premium Valuation with Faster Growth; Two Sit Below the Middle on Valuation and Growth Cut on EV / EBITDA vs the sector median (21.1x) (rows) and revenue growth vs the covered median (9%) (columns) · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Priced up and Growing Above-median multiple · above-median revenue growth 3 names IDEXX Laboratories, Inc. (IDXX) · Repligen Corporation (RGEN) · KORU Medical Systems, Inc. (KRMD) IDEXX Laboratories, Inc. (IDXX), Repligen Corporation (RGEN) and KORU Medical Systems, Inc. (KRMD) sit above the middle on both the forward earnings mark and revenue growth. This is the group whose recurring pull-through and menu breadth are being taken at face value by the market. Priced up on Slower Growth Above-median multiple · below-median revenue growth 3 names Bio-Rad Laboratories, Inc. (BIO) · Neogen Corporation (NEOG) · Maravai LifeSciences Holdings, Inc. (MRVI) Bio-Rad Laboratories, Inc. (BIO), Neogen Corporation (NEOG) and Maravai LifeSciences Holdings, Inc. (MRVI) carry above-middle marks on below-middle growth. The mark is associated with what buyers expect from the installed base and the reagent stream rather than from the current top line. Growing Ahead of the Mark Below-median multiple · above-median revenue growth 3 names Abbott Laboratories (ABT) · Waters Corporation (WAT) · DexCom, Inc. (DXCM) Abbott Laboratories (ABT), Waters Corporation (WAT) and DexCom, Inc. (DXCM) grow above the middle while marked below it. Scale and capital-equipment exposure sit alongside that combination in this set, and both are questions of revenue mix rather than of growth. Below on Both Measures Below-median multiple · below-median revenue growth 2 names Koninklijke Philips N.V. (PHG) · Inspire Medical Systems, Inc. (INSP) Koninklijke Philips N.V. (PHG) and Inspire Medical Systems, Inc. (INSP) sit below the middle on both measures, on the 11 companies with a forward estimate. Both carry procedure and hospital capital exposure, which is the pattern to test against contracted service and consumables revenue.

  11. 11
    03 · GROWTH VS PROFITABILITY

    Names Clearing Both the Growth and Margin Bars Sit Mid-Range; Those Clearing Neither Sit Above Them

    Quadrant chart of the 11 rated companies by revenue growth and EBITDA margin, with median multiple per quadrant.

    Plotting growth against margin for the 11 companies with both estimates, the names clearing both the 9% growth and 21% margin bars sit mid-range on multiple, while names clearing neither sit above them. That's a counterintuitive pattern worth sitting with rather than explaining away. It suggests the market is pricing something beyond growth and margin alone in this sector.

    Everything on this page

    03 · GROWTH VS PROFITABILITY Names Clearing Both the Growth and Margin Bars Sit Mid-Range; Those Clearing Neither Sit Above Them Revenue growth (CY2027E, x-axis) vs EBITDA margin (CY2026E, y-axis) · 11 companies with both estimates · cuts at the covered medians (9% growth, 21% margin) · median EV/EBITDA per quadrant · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Quadrant cuts are the covered set's medians. Quadrant medians on names with a meaningful EV/EBITDA (balanced n=5; margin-only n=1; growth-only n=1; neither n=4). Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 0% 5% 10% 15% 10% 20% 30% MARGIN ONLY median 9.0x BALANCED median 19.4x NEITHER median 25.6x GROWTH ONLY median 21.1x NEOG BIO INSP PHG MRVI ABT IDXX WAT DXCM RGEN KRMD x: revenue growth (CY2027E) · y: EBITDA margin (CY2026E) HOW TO READ THIS Read across for revenue growth against the middle of the covered names and up for reported margin against the middle. Five of the 11 companies with a forward estimate clear both bars — Abbott Laboratories (ABT), IDEXX Laboratories, Inc. (IDXX), Waters Corporation (WAT), DexCom, Inc. (DXCM) and Repligen Corporation (RGEN) — and that group sits at 19.4x. The balanced median rests on 5 names and is lifted by RGEN at 48.5x. Rule of 40 (revenue growth + EBITDA margin ≥ 40%): 3 of 11 names clear it (IDXX, WAT, DXCM).

  12. 12
    03 · THE AGENDA

    Where a Diagnostics Business Sits in This Range Tracks with Mix, Pricing, Retention and Capital Allocation

    List of questions on mix, pricing, retention and capital allocation that track with where a business sits in this range.

    Based on everything shown so far, we frame the open questions for an owner or acquirer around revenue mix, pricing power, retention and capital allocation. These are the levers that appear to move where a business sits in this range. They're observations for discussion, not a prescribed plan.

    Everything on this page

    03 · THE AGENDA Where a Diagnostics Business Sits in This Range Tracks with Mix, Pricing, Retention and Capital Allocation NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12 Convert Placements into Contracted Pull-Through The marks at the top of this range sit with businesses whose revenue arrives after the instrument is placed. The operating question is what share of revenue is consumables and service under contract, and how long that contract runs. What changes the answer: Renewal history, contract tenor and reagent exclusivity across the placed base. Widen the Menu on the Platform Already in the Field Menu expansion raises pull-through per placement without a new capital sale, which is the arithmetic behind the consumables-led groups in this set. Cadence of launches and utilisation per site are the measures that show whether it is working. What changes the answer: Test volumes per site and the launch cadence on the current platform. Sequence Spend Against Coverage and Clearance Gates Clearance scope, CLIA-waived status and coding decisions govern which sites of care can run a test and when revenue can ramp. Capital committed ahead of those gates carries a different risk than capital committed behind them. What changes the answer: Where each assay stands on clearance, coverage and IVDR transition work. Decide Build-Versus-Buy on the End-Market Ballast Veterinary, food safety and bioprocess adjacencies dampen exposure to hospital and academic capital cycles, and precedent transactions in this record show buyers crossing into them. The choice is whether to build that exposure or acquire it. What changes the answer: How much of revenue depends on customer capital budgets in a given year.

  13. 13
    SECTION 04

    04

    Section divider introducing the precedent transaction record.

    Earnings frames the consumables deals in this record, and revenue frames the menu-stage ones. Next we walk through what buyers actually agreed to pay.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Earnings Frames for the Consumables Deals, Revenue Frames for the Menu-Stage Ones What buyers agreed to pay across the 9 transactions in this record, and which standard they used. 04 of 06 Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13

  14. 14
    04 · DEAL CASE STUDIES

    Precedent Transactions Set the Benchmark: What Buyers Agreed to Pay for Whole Diagnostics Companies

    Case study review of a precedent transaction with disclosed terms, illustrating how buyers valued a diagnostics company.

    We walk through one transaction from the record in detail, using the multiple disclosed on LTM financials at announcement. The complete list of transactions sits in the appendix for anyone who wants the full picture. These deal multiples sit on a different basis than the forward public multiples shown earlier, so we don't draw a spread between the two.

    Everything on this page

    04 · DEAL CASE STUDIES Precedent Transactions Set the Benchmark: What Buyers Agreed to Pay for Whole Diagnostics Companies 1 of 27 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 74 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 33 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14 Dec-2019 $130M Veracyte, Inc. acquires NanoString Technologies, Inc. EV / LTM revenue 1.1x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED Transactions in this sector are dominated by scaled diagnostics and life-science tools platforms buying menu, placements or channel, and the strategic fit in a deal of this shape is the pull-through behind the installed base. What that pattern suggests is a buyer paying for contracted reagent and service revenue alongside the instrument line. HOW THE TARGET WAS VALUED Majority acquisitions of consumables-led franchises here are customarily priced off EBITDA, with recurring pull-through stress-tested separately from one-time instrument revenue. Disclosed earnings multiples in this transaction record include 8.0x and 19.8x, and those are the reference points a consumables-led asset benchmarks against.

  15. 15
    SECTION 05

    05

    Section divider introducing the strategic implications for owners, boards and acquirers.

    The mix between instruments and consumables is the part an owner can actually move. Next we set out what this evidence points to for the people making that call.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS The Mix Between Boxes and Blades Is the Part an Owner Can Move What the evidence points to for owners, boards and acquirers in this sector. 05 of 06 Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15

  16. 16
    05 · STRATEGIC IMPLICATIONS

    A Wide Range Means Revenue Quality and Growth Durability Carry Real Value for Owners

    Summary of the questions this data raises for owners, boards and acquirers over the next twelve months.

    A range this wide means revenue quality and growth durability carry real value for owners of businesses in this sector. We frame this as a set of questions the data puts on the table, not as a recommendation. The pages that follow carry the full detail behind every figure referenced here.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS A Wide Range Means Revenue Quality and Growth Durability Carry Real Value for Owners NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16 FOR OWNERS Revenue Mix Is the Lever, and It Is Yours to Move The top of this range sits with reagent and consumables revenue, the bottom with placement and procedure exposure. Shifting the mix toward contracted pull-through, and lengthening the service annuity behind the placed base, changes the quality of the earnings the market is marking. FOR BOARDS Separate the Rebuilt Core from the Pandemic Comparative Growth framing in this sector only travels if the non-COVID base is visible underneath it, and the transaction record still carries pandemic-era revenue marks. Planning should run off the rebuilt core, with capital allocation sized to placements, menu launches and coverage timing rather than to a headline growth rate. FOR ACQUIRERS Precedent Transactions Favour Buyers Who Can Isolate the Pull-Through In this record, consumables-led assets were framed on earnings while menu-stage and reimbursement-stage assets were framed on revenue with structure behind the gates. Buyers able to underwrite contract tenor, reagent exclusivity and quality-system history have the clearer path on both frames.

  17. 17
    SECTION 06

    06

    Section divider introducing the appendix of comparables, methodology and sources.

    The remaining pages carry the full universe, the valuation basis and the source behind every figure in this report.

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17

  18. 18
    06 · PUBLIC COMPARABLES (1 OF 1)

    Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier

    Full table of the 26 companies in the universe, with the 11 rated names grouped by valuation tier.

    This table carries every rated company behind the medians shown earlier, shaded by whether it sits above or below the 21.1x sector median. The 15 companies without an eligible forward multiple are listed separately. Anyone checking a specific name against the charts earlier in this report can find it here.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/EBITDA above the sector median (21.1x); amber marks below · 11 rated companies; 15 not rated (no eligible EV/EBITDA) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 11 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV EV/EBITDA (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥25.6x · median 48.5x · 3 companies Maravai LifeSciences Holdings, Inc. MRVI Research-use detection platforms and reagents $2.2B 50.4x 7% 16% 26 Repligen Corporation RGEN Laboratory instruments and testing consumables $10.8B 48.5x 17% 21% 40 Bio-Rad Laboratories, Inc. BIO Procedure-based diagnostic and therapy devices $9.9B 27.2x 3% 15% 17 CORE — 15.3x–25.6x · median 21.1x · 5 companies Neogen Corporation NEOG Procedure-based diagnostic and therapy devices $4.4B 24.0x -4% 19% 18 IDEXX Laboratories, Inc. IDXX Clinical diagnostics and research instrumentation $42.8B 23.0x 9% 35% 45 KORU Medical Systems, Inc. KRMD Laboratory instruments and testing consumables $136M 21.1x 17% 4% 29 Waters Corporation WAT Clinical diagnostics and research instrumentation $48.6B 19.4x 10% 31% 46 DexCom, Inc. DXCM Procedure-based diagnostic and therapy devices $32.4B 17.0x 11% 32% 44 DISCOUNT — <15.3x · median 9.0x · 3 companies Abbott Laboratories ABT Procedure-based diagnostic and therapy devices $203B 13.6x 9% 27% 36 Inspire Medical Systems, Inc. INSP Procedure-based diagnostic and therapy devices $1.8B 9.0x 4% 21% 26 Koninklijke Philips N.V. PHG Procedure-based diagnostic and therapy devices $30.6B 7.7x 4% 18% 23

  19. 19
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    First page of the full list of precedent transactions with disclosed terms, sorted newest first.

    This is the transaction record behind the case study shown earlier, listed newest first with the multiple disclosed at announcement where available. Some records carry data-quality notes and are shown as recorded in the filing. The remaining transactions continue on the next page.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 27 transactions with disclosed terms in this tier (60 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 74 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 33 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 27 transactions shown; the rest are in the companion workbook. Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Apr-2026 CJ CheilJedang Corp. → EDAP TMS SA n/a n/a 8.0x CJ CheilJedang Corp. agreed terms for EDAP TMS SA in April 2026 at 8.0x EBITDA, recorded as announced. The deal value unit is unresolved in the filing, so the multiple rather than the headline size carries the read. Aug-2025 Takeaway.com N.V. → Veracyte SAS n/a 6.4x n/a Takeaway.com N.V. agreed to acquire Veracyte SAS in August 2025 at 6.4x revenue, recorded as announced. Pricing on revenue rather than earnings is the convention where the menu is still expanding and coverage is being built out. Jul-2025 Waters Corporation → Becton, Dickinson and Company (BD Biosciences & Diagnostic Solutions) n/a n/a 19.8x Waters Corporation agreed terms for Becton, Dickinson and Company (BD Biosciences & Diagnostic Solutions) in July 2025 at 19.8x EBITDA, recorded as announced. Carve-outs of this kind travel with supply and transition arrangements, and the earnings frame suggests the… Dec-2023 Roche Diagnostics Limited → LumiraDx Limited n/a 3.6x n/a Roche Diagnostics Limited agreed to acquire LumiraDx Limited in December 2023 at 3.6x revenue, recorded as announced. A scaled diagnostics buyer taking a sample-to-answer platform on a revenue frame is consistent with paying for placements and menu ahead of current… Apr-2023 Mars, Incorporated → Heska Corporation n/a n/a 8.8x Mars, Incorporated agreed terms for Heska Corporation in April 2023 at 8.8x EBITDA; the transaction is recorded as terminated. Non-clinical adjacencies such as veterinary diagnostics attract buyers from outside the clinical channel. Jul-2022 SD Biosensor, Inc. → Meridian Bioscience, Inc. n/a 0.7x 8.8x SD Biosensor, Inc. agreed terms for Meridian Bioscience, Inc. in July 2022 at 0.7x revenue and 8.8x EBITDA; the transaction is recorded as terminated. The deal value unit is unresolved in the filing, so the two multiples carry the read. Jan-2022 Quidel Corporation → Ortho Clinical Diagnostics Holdings plc n/a 3.8x n/a Quidel Corporation agreed to acquire Ortho Clinical Diagnostics Holdings plc in January 2022 at 3.8x revenue, recorded as announced. Buying a placed base and a clinical assay menu on that frame points to placements and pull-through as the asset. Mar-2021 Roche Holding Ltd → GenMark Diagnostics, Inc. n/a 10.4x n/a Roche Holding Ltd agreed to acquire GenMark Diagnostics, Inc. in March 2021 at 10.4x revenue, with the deal value unit unresolved in the filing and the transaction recorded as announced. That revenue multiple sits above the later revenue-framed deals in this record… Jan-2021 Hill-Rom, Inc. → Bardy Diagnostics, Inc. n/a 10.0x 11.3x Hill-Rom, Inc. agreed to acquire Bardy Diagnostics, Inc. in January 2021 at 10.0x revenue and 11.3x EBITDA, recorded as announced. A device group adding cardiac monitoring diagnostics shows buyers extending into adjacent testing modalities.

  20. 20
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    Second page of the full list of precedent transactions with disclosed terms, sorted newest first.

    This page completes the transaction list started on the previous page, on the same basis. Together the two pages carry every disclosed-terms transaction in this record.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 27 transactions with disclosed terms in this tier (60 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 74 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 33 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 27 transactions shown; the rest are in the companion workbook. Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Aug-2020 Thermo Fisher Scientific Inc. → QIAGEN N.V. n/a 4.6x n/a Dec-2019 Veracyte, Inc. → NanoString Technologies, Inc. $130M 1.1x n/a Value shown as recorded in the filing; deal value unit unresolved. Jun-2017 PerkinElmer, Inc. → EUROIMMUN US, Inc. n/a 5.0x 22.6x Value shown as recorded in the filing; deal value unit unresolved. Sep-2016 Danaher Corporation → Cepheid n/a 5.9x n/a Feb-2016 Abbott → Alere Inc. n/a 3.1x 25.1x Sep-2013 bioMérieux SA → BioFire Diagnostics, LLC n/a 6.9x 6.1x Value shown as recorded in the filing; deal value unit unresolved. Apr-2012 Hologic, Inc. → Gen-Probe Incorporated n/a 6.4x 20.3x Jul-2011 TPG Capital → Immucor, Inc. n/a 3.4x 9.5x Value shown as recorded in the filing; deal value unit unresolved. May-2011 Danaher Corporation → Cepheid n/a 7.1x n/a Value shown as recorded in the filing; deal value unit unresolved.

  21. 21
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    Explanation of the data sources, valuation basis and exclusions behind the figures in this report.

    This report is built on market data and consensus estimates as of September 2026, with company disclosures drawn from SEC filings. We set out here what was included, what was excluded and on what basis, so every figure in the body can be traced back to where it came from.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice 21 VALUATION BASIS Primary valuation basis: EV / EBITDA on CY2027E consensus (11 of 26 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Diagnostic and Testing Equipment and it clears the coverage gate with 11 of 26 companies (42%). EV / Revenue, P / E are carried as a cross-check. The set earns: 11 of the 15 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. DATA QUALITY & EXCLUSIONS 81 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 921 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (920) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  22. 22

    The Higher Marks in This Set Sat with Consumables Annuities Rather than with Growth.

    Closing slide restating that the higher marks in this set sat with consumables annuities rather than with growth.

    The higher marks in this set sat with consumables annuities rather than with growth. The companion tables alongside this deck carry the full universe and source index for any figure a client wants to trace further.

    Everything on this page

    The Higher Marks in This Set Sat with Consumables Annuities Rather than with Growth. NeuraCap AI — Diagnostic and Testing Equipment Coverage September 2026 · Prepared by NeuraCap AI · Confidential Diagnostic and Testing Equipment Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 22

Sources and methodology

This report covers Diagnostic and Testing Equipment (Health Care › Health Care Equipment and Services › Diagnostic and Testing Equipment) with market data and consensus estimates as of September 28, 2026. The company universe is the 26 listed companies whose core business is Diagnostic and Testing Equipment according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Abbott Laboratories (ABT), Bio-Rad Laboratories, Inc. (BIO), Carlsmed, Inc. (CARL), CeriBell, Inc. (CBLL), CapsoVision, Inc. (CV), DexCom, Inc. (DXCM), Daxor Corporation (DXR), IDEXX Laboratories, Inc. (IDXX), Illumina, Inc. (ILMN), Inspire Medical Systems, Inc. (INSP), IRadimed Corporation (IRMD), KORU Medical Systems, Inc. (KRMD), Lucid Diagnostics Inc. (LUCD), Mesa Laboratories, Inc. (MLAB), Maravai LifeSciences Holdings, Inc. (MRVI), MaxCyte, Inc. (MXCT), Nautilus Biotechnology, Inc. (NAUT), Neogen Corporation (NEOG), Anbio Biotechnology Class A Ordinary Shares (NNNN), OraSure Technologies, Inc. (OSUR), Koninklijke Philips N.V. (PHG), Repligen Corporation (RGEN), Senseonics Holdings, Inc. (SENS), SS Innovations International, Inc. (SSII), Waters Corporation (WAT), Exagen Inc. (XGN). The market map groups them by business vertical — Procedure-based diagnostic and therapy devices: 12 companies (ABT, DXCM, PHG, BIO, NEOG, INSP, IRMD, CBLL, SSII, SENS, CV, LUCD); Laboratory instruments and testing consumables: 5 companies (RGEN, NNNN, KRMD, OSUR, DXR); Clinical diagnostics and research instrumentation: 4 companies (WAT, IDXX, ILMN, XGN); Research-use detection platforms and reagents: 3 companies (MRVI, NAUT, MXCT); Adjacent models: 2 companies (MLAB, CARL). 11 of the 26 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

Scope and company universe

This report covers Diagnostic and Testing Equipment (Health Care › Health Care Equipment and Services › Diagnostic and Testing Equipment) with market data and consensus estimates as of September 28, 2026. The company universe is the 26 listed companies whose core business is Diagnostic and Testing Equipment according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Abbott Laboratories (ABT), Bio-Rad Laboratories, Inc. (BIO), Carlsmed, Inc. (CARL), CeriBell, Inc. (CBLL), CapsoVision, Inc. (CV), DexCom, Inc. (DXCM), Daxor Corporation (DXR), IDEXX Laboratories, Inc. (IDXX), Illumina, Inc. (ILMN), Inspire Medical Systems, Inc. (INSP), IRadimed Corporation (IRMD), KORU Medical Systems, Inc. (KRMD), Lucid Diagnostics Inc. (LUCD), Mesa Laboratories, Inc. (MLAB), Maravai LifeSciences Holdings, Inc. (MRVI), MaxCyte, Inc. (MXCT), Nautilus Biotechnology, Inc. (NAUT), Neogen Corporation (NEOG), Anbio Biotechnology Class A Ordinary Shares (NNNN), OraSure Technologies, Inc. (OSUR), Koninklijke Philips N.V. (PHG), Repligen Corporation (RGEN), Senseonics Holdings, Inc. (SENS), SS Innovations International, Inc. (SSII), Waters Corporation (WAT), Exagen Inc. (XGN). The market map groups them by business vertical — Procedure-based diagnostic and therapy devices: 12 companies (ABT, DXCM, PHG, BIO, NEOG, INSP, IRMD, CBLL, SSII, SENS, CV, LUCD); Laboratory instruments and testing consumables: 5 companies (RGEN, NNNN, KRMD, OSUR, DXR); Clinical diagnostics and research instrumentation: 4 companies (WAT, IDXX, ILMN, XGN); Research-use detection platforms and reagents: 3 companies (MRVI, NAUT, MXCT); Adjacent models: 2 companies (MLAB, CARL). 11 of the 26 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

81 records failed a validation gate and never feed a statistic in this report (74 excluded from aggregate; 7 quarantined). Each exclusion, with its reason: CARL — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CARL — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CARL — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CARL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CARL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CARL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CARL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CBLL — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CBLL — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CBLL — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CBLL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CBLL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CBLL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CBLL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CV — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CV — Implied EBITDA margin -173.2% outside the plausible band [-100%, 80%] (effect: quarantined) · CV — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CV — Implied EBITDA margin -104.8% outside the plausible band [-100%, 80%] (effect: quarantined) · CV — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CV — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CV — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CV — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DXR — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · KRMD — EBITDA 390000.0000 is below the $1000000 materiality floor; any multiple would be meaningless (effect: excluded from aggregate) · KRMD — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · further items are listed in the companion tables.

Primary valuation basis and how it was chosen

Primary valuation basis: EV / EBITDA on CY2027E consensus (11 of 26 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Diagnostic and Testing Equipment and it clears the coverage gate with 11 of 26 companies (42%). EV / Revenue, P / E are carried as a cross-check. The set earns: 11 of the 15 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 11 of 26 companies; EV / rEVenue: 24 of 26 companies; P/E: 13 of 26 companies. 4 companies show a non-meaningful EV / EBITDA denominator and are excluded from that statistic. 11 companies show a non-meaningful P / E denominator and are excluded from that statistic.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥25.6x, Core 15.3x–25.6x, Discount <15.3x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 21.1x = median(ev_ebitda CY2027E) (11 rated companies) · 48.5x = median(ev_ebitda CY2027E) within Premium tier (n=3) · 21.1x = median(ev_ebitda CY2027E) within Core tier (n=5) · 9.0x = median(ev_ebitda CY2027E) within Discount tier (n=3) · 20.3x = median(ev_ebitda CY2027E) | growth ≥ 9% (n=6) · 24.0x = median(ev_ebitda CY2027E) | growth < 9% (n=5) · 18.2x = median(ev_ebitda CY2027E) | EBITDA margin ≥ 21% (n=6) · 24.0x = median(ev_ebitda CY2027E) | EBITDA margin < 21% (n=5) · 25% = median Rule of 40 score (revenue growth + EBITDA margin) (n=11) · 19.4x = median(ev_ebitda CY2027E) within balanced quadrant (n=5) · 9.0x = median(ev_ebitda CY2027E) within marginOnly quadrant (n=1) · 21.1x = median(ev_ebitda CY2027E) within growthOnly quadrant (n=1) · 25.6x = median(ev_ebitda CY2027E) within neither quadrant (n=4) · 48.5x = ev_ebitda CY2027E for RGEN (quadrant outlier)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Diagnostic and Testing Equipment recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 60 transactions were recorded for this industry; 27 are shown. 33 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 30 × deal value unit unresolved; 35 × no evidence record; 6 × duplicate precedent id; 3 × divestiture roles reassigned. Case studies lead with the 1 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 925 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

Sources linked in the report

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Diagnostic and Testing Equipment?

Company valuation reports run the same method against a single business — public or private.